Maze Therapeutics Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
141
- Stock Symbol
-
MAZE
- Investments
-
2
- Share Price
-
$33.90
- (As of Monday Closing)
Maze Therapeutics General Information
Description
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Contact Information
Website
www.mazetx.comCorporate Office
- 171 Oyster Point Boulevard
- Suite 300
- South San Francisco, CA 94080
- United States
Corporate Office
- 171 Oyster Point Boulevard
- Suite 300
- South San Francisco, CA 94080
- United States
Maze Therapeutics Timeline
Maze Therapeutics Stock Performance
As of 16-Nov-2026, Maze Therapeutics’s stock price is $33.90. Its current market cap is $1.85B with 54.7M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $33.90 | $34.34 | $21.95 - $53.65 | $1.85B | 54.7M | 712K | -$2.67 |
Maze Therapeutics Financials Summary
As of 30-Sep-2026, Maze Therapeutics has a trailing 12-month revenue of $20M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,159,162 | 1,633,837 | ||
| Revenue | 20,000 | 0 | 167,500 | 0 |
| EBITDA | (162,445) | (140,496) | 52,049 | (98,281) |
| Net Income | (151,472) | (131,120) | 52,231 | (100,415) |
| Total Assets | 511,557 | 397,127 | 240,542 | 71,504 |
| Total Debt | 59,643 | 23,306 | 26,628 | 49,623 |
Maze Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Maze Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Maze Therapeutics Comparisons
Industry
Financing
Details
Maze Therapeutics Competitors (45)
One of Maze Therapeutics’s 45 competitors is Centrose, a Venture Capital-Backed company based in Madison, WI.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Aro Biotherapeutics | Venture Capital-Backed | Philadelphia, PA | ||||
| Xenetic Biosciences | Corporation | Framingham, MA | ||||
| Inhibrx | Formerly VC-backed | La Jolla, CA | ||||
| Cantex Pharmaceuticals | Formerly VC-backed | Weston, FL |
Maze Therapeutics Patents
Maze Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026193408-A2 | Apol1 inhibitors and methods of use thereof | Pending | 14-Mar-2025 | ||
| WO-2026183125-A1 | Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof | Pending | 25-Feb-2025 | ||
| WO-2026183127-A1 | Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof | Pending | 25-Feb-2025 | ||
| WO-2026183128-A1 | Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof | Pending | 25-Feb-2025 | ||
| WO-2026183129-A1 | Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof | Pending | 25-Feb-2025 | C07D471/04 |
Maze Therapeutics Signals
Maze Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Maze Therapeutics Investments (2)
Maze Therapeutics’s most recent deal was a Joint Venture with Broadwing Bio. The deal was made on 07-Dec-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Broadwing Bio | 07-Dec-2020 | Joint Venture | Biotechnology | ||
| Contour Therapeutics | 07-Dec-2020 | Joint Venture | Drug Discovery |
Maze Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Maze Therapeutics FAQs
-
When was Maze Therapeutics founded?
Maze Therapeutics was founded in 2018.
-
Where is Maze Therapeutics headquartered?
Maze Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of Maze Therapeutics?
Maze Therapeutics has 141 total employees.
-
What industry is Maze Therapeutics in?
Maze Therapeutics’s primary industry is Drug Discovery.
-
Is Maze Therapeutics a private or public company?
Maze Therapeutics is a Public company.
-
What is Maze Therapeutics’s stock symbol?
The ticker symbol for Maze Therapeutics is MAZE.
-
What is the current stock price of Maze Therapeutics?
As of 16-Nov-2026 the stock price of Maze Therapeutics is $33.90.
-
What is the current market cap of Maze Therapeutics?
The current market capitalization of Maze Therapeutics is $1.85B.
-
What is Maze Therapeutics’s current revenue?
The trailing twelve month revenue for Maze Therapeutics is $20M.
-
Who are Maze Therapeutics’s competitors?
Centrose, Aro Biotherapeutics, Xenetic Biosciences, Inhibrx, and Cantex Pharmaceuticals are some of the 45 competitors of Maze Therapeutics.
-
What is Maze Therapeutics’s annual earnings per share (EPS)?
Maze Therapeutics’s EPS for 12 months was -$2.67.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process